MAPK1 and myeloid sarcoma: Through a dual evaluation approach, this network-based analysis could effectively yield top modules evaluated by the presence of MS FDA-approved drug target genes: HDAC1, IL2RA, KEAP1 and RELA. Other central genes present within top modules are suggested as potential drug targets for MS: GRB2, JAK2, MAPK1 and STAT3. The independent gene set enrichment results of both GeneMSA and IMSGC top modules supported the hypothesis of epigenetic factors involved in dysregulation of genes in MS.